neuroClues

neuroClues has developed a CE-marked Class IIa portable eye-tracking headset that quantifies eye movements to provide objective digital biomarkers for early diagnosis and monitoring of neurological diseases. The system can record up to 800 infrared images per eye per second and delivers results within minutes. It has been validated in clinical research cohorts such as the Iceberg study for Parkinson’s disease at La Salpêtrière Hospital. The company aims to expand into primary care after initial adoption by neurologists and specialists. Regulatory approval processes are underway for US commercialization via FDA submission planned for late 2024/2025. Clinical studies have demonstrated utility in identifying early-stage Parkinson's disease and tracking progression objectively.